We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$191M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Consumer Staples 0.52%
3 Consumer Discretionary 0.08%
4 Financials 0.04%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
76
Ardelyx
ARDX
$976M
$2.76M 0.19%
315,955
– –
XENE icon
77
Xenon Pharmaceuticals
XENE
$5.85B
$2.55M 0.18%
432,800
+227,000
+110% +$1.56M
RXDX
78
DELISTED
Ignyta, Inc.
RXDX
$2.36M 0.16%
435,260
-911,800
-68% -$6.07M
IONS icon
79
PUT
Ionis Pharmaceuticals
IONS
$10.6B
$2.33M 0.16%
+100,000
New +$3.23M
TARA icon
80
Protara Therapeutics
TARA
$235M
$2.21M 0.15%
6,875
– –
MGCD
81
DELISTED
MGC Diagnostics Corporation
MGCD
$2.19M 0.15%
336,287
– –
ADYX
82
DELISTED
Adynxx Inc
ADYX
$2.15M 0.15%
32,033
– –
PGNX
83
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$2.11M 0.15%
+500,000
New +$2.41M
EIGR
84
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.08M 0.14%
3,497
– –
RLYP
85
PUT
DELISTED
RELYPSA INC COM
RLYP
$1.85M 0.13%
+100,000
New +$1.76M
AFMD
86
DELISTED
Affimed
AFMD
$1.82M 0.13%
+73,430
New +$2.68M
DSCI
87
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.71M 0.12%
432,884
– –
GNMX
88
DELISTED
Aevi Genomic Medicine Inc
GNMX
$1.67M 0.12%
+300,000
New +$1.58M
PETX
89
DELISTED
Aratana Therapeutics, Inc.
PETX
$1.62M 0.11%
256,500
-35,300
-12% -$227K
ABMD
90
DELISTED
Abiomed Inc
ABMD
$1.61M 0.11%
14,700
+5,000
+52% +$497K
CBPO
91
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$1.49M 0.1%
14,000
– –
VCEL icon
92
Vericel Corp
VCEL
$2.21B
$1.25M 0.09%
557,342
-689,970
-55% -$1.99M
GMED icon
93
Globus Medical
GMED
$11.1B
$1.19M 0.08%
+50,000
New +$1.2M
ABEOW
94
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$1.07M 0.07%
1,259,636
– –
BCLI
95
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$964K 0.07%
26,667
– –
LPCN icon
96
CALL
Lipocine
LPCN
$17.7M
$912K 0.06%
+17,647
New +$2.73M
LPCN icon
97
PUT
Lipocine
LPCN
$17.7M
$865K 0.06%
+16,729
New +$2.59M
PZRX
98
DELISTED
PhaseRx, Inc.
PZRX
$852K 0.06%
+200,000
New +$988K
CSBR icon
99
Champions Oncology
CSBR
$69.2M
$801K 0.06%
372,597
– –
LXRX icon
100
Lexicon Pharmaceuticals
LXRX
$1.04B
$718K 0.05%
+50,000
New +$678K
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $191M of net new capital in Q2 2016, opening 57 new positions and adding to 37 existing holdings. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $12.4M trimmed.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.